Quarterly report pursuant to Section 13 or 15(d)

Segment Information

v2.4.0.8
Segment Information
3 Months Ended
Sep. 30, 2013
Segment Information

H. Segment Information:

The Company has two reportable segments based on the nature of products (biotechnology and clinical controls). Following is financial information relating to the Company’s reportable segments (in thousands):

 

     Quarter Ended
September 30,
 
     2013     2012  

External sales

    

Biotechnology

   $ 73,190      $ 69,503   

Clinical Controls

     12,478        5,522   
  

 

 

   

 

 

 

Consolidated net sales

   $ 85,668      $ 75,025   
  

 

 

   

 

 

 

Earnings before income taxes

    

Biotechnology

   $ 39,378      $ 36,994   

Clinical Controls

     2,285        2,103   
  

 

 

   

 

 

 

Segment earnings before income taxes

     41,663        39,097   

Unallocated corporate expenses and equity method investee losses

     (2,009     (1,111
  

 

 

   

 

 

 

Consolidated earnings before income taxes

   $ 39,654      $ 37,986